To include your compound in the COVID-19 Resource Center, submit it here.

MGCD265: Additional Phase I/II data

MethylGene reported additional data from the Phase I portion of the ongoing, open-label, dose-escalation Phase I/II 265-103 trial evaluating oral MGCD256 in combination with either erlotinib or docetaxel.

Read the full 287 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE